AuraVax Therapeutics Enters into Exclusive License Option Agreement with the University of Houston for Intranasal Vaccine Platform
Transaction supports development of AuraVax's lead COVID-19 Intranasal Vaccine
HOUSTON, Oct. 12, 2020 /PRNewswire/ -- AuraVax Therapeutics Inc. (www.auravax.com), a Houston, TX based biotech company developing novel vaccines to help patients defeat debilitating respiratory diseases such as SARS-CoV-2 (COVID-19), today announced it has entered into an exclusive license option agreement with the University of Houston with respect to the intellectual property covering a novel intranasal vaccine technology. Under terms of this agreement, AuraVax has the option to exclusively license patents covering this technology.
"We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine platform to address a multitude of respiratory viruses, starting with COVID-19. We plan to stop COVID-19, a respiratory virus, at its point of entry -- the nasal cavity -- and we believe our intranasal platform is a differentiated approach that will lead to a vaccine with increased efficacy to create sustained immunity to COVID-19," said Dr. Navin Varadarajan, AuraVax co-founder and M.D. Anderson Professor of Chemical and Biomolecular Engineering at the University of Houston.
"AuraVax, being created by a UH professor, is the ideal partner for us, and what better cause than to advance the creation of a vaccine to COVID-19, arguably the primary challenge facing our generation. The partnership has my wholehearted support," said Amr Elnashai, University of Houston vice president for research and technology transfer.
"The race for more effective ways of vaccinating against COVID-19 and other respiratory diseases has led to a broad and extensive focus on various protective mechanisms of action. Based on pre-clinical work, our technology not only elicits a mucosal immune response, but also systemic immunity. We believe AuraVax has a competitive advantage given the immune responses and a supply chain that is well-suited for widespread distribution and self-administration distribution," stated Dr. Varadarajan.
About AuraVax
AuraVax Therapeutics Inc. ("AuraVax") is a privately held biotechnology company developing a proprietary and differentiated platform of vaccines against various respiratory viruses including COVID-19. Its next-generation vaccine platform combines the potential of in-home administration with the ability to deliver complete immunity. The technology has been validated for COVID-19 in initial animal studies and results in immunity measured by both B-cell and T-cell responses. For more information, go to www.auravax.com
About the University of Houston
The University of Houston is a Carnegie-designated Tier One public research university recognized with a Phi Beta Kappa chapter for excellence in undergraduate education. UH serves the globally competitive Houston and Gulf Coast Region by providing world-class faculty, experiential learning and strategic industry partnerships. Located in the nation's fourth-largest city and one of the most ethnically and culturally diverse regions in the country, UH is a federally designated Hispanic and Asian American Serving institution with enrollment of more than 47,000 students.
Contact:
Matthew J. Meyer, [email protected]
Navin Varadarajan, [email protected]
SOURCE AuraVax Therapeutics Inc.
Share this article